DOCSLIB.ORG

Photosensitizing Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LFFeb05 pgs78-118 12/29/04 4:57 PM Page 86 Sunlight and the Skin MANY MEDICATIONS, TOPICAL SOLUTIONS AND EVEN SOME FOODS CAN CAUSE THE SKIN TO BURN OR BREAK OUT IN A RASH WHEN EXPOSED TO ULTRAVIOLET LIGHT. THE CONSEQUENCES CAN RANGE FROM ITCHINESS TO AN UNCOMFORTABLE RASH AND BURNS. IT IS CRITICAL THAT EVERY SALON OWNER POST A CHART OF PHOTOSENSITIVE MEDICATIONS AND AGENTS IN A CONSPICUOUS LOCATION. IF A CLIENT IS TAKING A MEDICATION THAT ISN’T LISTED, HE OR SHE SHOULD CONSULT WITH A PHYSICIAN OR PHARMACIST BEFORE BEING EXPOSED TO ULTRAVIOLET LIGHT—INDOORS OR OUTDOORS. The most common photosensitizing materials are listed on the ■ Brand names of products should be considered only as examples; following pages. This is not a list of every material that could have they do NOT represent all names under which the generic product photosensitizing effects. Before using the list, you should be aware of may be sold. the following: The following list was prepared by Jerome I. Levine, M.S., R.Ph., of the ■ NOT all individuals who use or take these medications will experience U.S. Food and Drug Administration. The list was published under the title a photosensitive reaction. Also, an individual who experiences a “Medications That Increase Sensitivity To Light: A 1990 Listing.” The FDA photosensitive reaction on one occasion will NOT necessarily has confirmed this list to be the most recent. The mention of commercial experience it again or every time. products, their sources or their use in connection with material reported ■ A medication will NOT cause the same degree of skin reaction in herein is not to be construed as either an actual or implied endorsement of all individuals. such products by the Department of Health and Human Services. Cromolyn Intal Inhaler Antiasthmatic Reported Photosensitizing Medications Cyclobenzaprine Flexeril Anti-skeletal, Muscle spasms Cyproheptadine Periactin Antihistamine, Antiserotonergic Generic Name Brand Name Therapeutic Class Dacarbazine DTIC-Dome Anti-Hodgkin’s disease, Antimetabolite Acetazolamide Diamox Anticonvulsant, Antiglaucoma diuretic Danazol Danocrine Gonadotropin inhibitor Amiloride + Hydrochlorothizide Moduretic Antihypertensive, Thiazide diuretic Demeclocycline Declomycin Antibiotic Amiodarone Cordarone (15%) Antiarrhythmic Desipramine Norpramin Antidepressant (tricyclic) Amitriptyline Elavil Antidepressant (tricyclic) Desipramine Pertofrane Antidepressant (tricyclic) Amitriptyline Endep Antidepressant (tricyclic) Dexchlorpheniramine Polaramine Antihistamine Amoxapine Asendin (<1%) Antidepressant (tricyclic) Diclofenac Voltaren (<1%) NSAID,* Antiarthritic Astemizole Hismanal Antihistamine Diflunisal Dolobid (<1%) NSAID,* Antiarthritic Atenolol + Chlorthalidone Tenoretic Beta-adrenergic blocker, Thiazide Diltiazem Cardizem (<1%) Antianginal, Antihypertensive, Calcium diuretic channel blocker Auranofin Ridaura Antiarthritic, Gold compound Diphenhydramine Benadryl Antihistamine Azatadine Optimine Antihistamine Diphenylpyraline Hispril Spansule Antihistamine Azatidine + Pseudoephedrine Trinalin Repetabs Antihistamine, Decongestant Doxepin Sinequan Antidepressant (tricyclic) Bendroflumethiazide Naturetin Antihypertensive, Thiazide diuretic Doxycycline Vibramycin Antibiotic Benzthiazide Exna Antihypertensive, Thiazide diuretic Doxycycline Hyclate Doryx Antibiotic Bromodiphenhydramine Ambenyl Antihistamine Enalapril Vasotec Antihypertensive Brompheniramine Dimetane Antihistamine Enalapril + Hydrochlorothiazide Vaseretic Antihypertensive, Thiazide diuretic Captopril Capoten Antihypertensive Erythromycin Ethylsuccinate + Sulfisoxazole Pediazole Antibiotic Captopril + Hydrochlorothiazide Capozide Antihypertensive, Thiazide diuretic Estrogens Contraceptive, oral Female sex hormone Carbamazepine Tegretol Analgesic, Anticonvulsant Estrogens Estrogens Female sex hormone Chlordiazepoxide + Amitriptyline Limbitrol Antidepressant (tricyclic), Tranquilizer Ethionamide Trecator-SC Anti-infective, Antituberculosis Chlorothiazide Diuril Antihypertensive, Thiazide diuretic Etretinate Tegison Antipsoriatic Chlorpheniramine Chlorpheniramine Antihistamine Floxuridine FUDR Injectable Antimetabolite, Antineoplastic Chlorpheniramin + D-Pseudoephedrine Deconamine Antihistamine, Decongestant Flucytosine Ancobon Antifungal Chlorpheniramine + Phenylpropanolamine Ru-Tuss II Antihistamine, Decongestant Fluorouracil Adrucil Antineoplastic Chlorpromazine Thorazine Antiemetic, Tranquilizer Fluorouracil Efudex Antineoplastic Chlorpropamide Diabinese Antidiabetic (oral), Sulfonylurea Fluorouracil Fluorouracil Antineoplastic Chlorprothixene Taractan Antiemetic, Tranquilizer Fluphenazine Prolixin Antipsychotic, Tranquilizer Chlorthalidone Hygroton Antihypertensive, Thiazide diuretic Fluphenazine Permitil Antipsychotic, Tranquilizer Chlorthalidone Thalitone Antihypertensive, Thiazide diuretic Flurbiprofen Ansaid NSAID,* Antiarthritic Chlorthalidone + Reserpine Demi-Regroton Antihypertensive, Thiazide diuretic Flutamide Eulexin Antimetastatic (prostatic carcinoma) Chlorthalidone + Reserpine Regroton Antihypertensive, Thiazide diuretic Furosemide Lasix Antihypertensive, Diuretic Ciprofloxacin Cipro (<1%) Anti-infective Gentamicin Garamycin Antibiotic Clemastine Tavist Antihistamine Glipizide Glucotrol Antidiabetic (oral),Sulfonylurea Clofazime Lamprene (<1%) Antibacterial, Antileprosy agent Glyburide Diabeta Antidiabetic (oral),Sulfonylurea Clonidine Chlorthalidone + Combipres Antihypertensive, Thiazide diuretic Glyburide Micronase Antidiabetic (oral), Sulfonylurea Coal Tar Estar Gel Antipsoriatic, Eczema Gold Salts (compounds) Solganal Antiarthritic, Gold compound Coal Tar Balnetar Antipsoriatic, Eczema Gold Sodium Thiomalate Myochrysine Antiarthritic, Gold compound Contraceptive, oral Estrogen Birth control pill, Female sex hormone Griseofulvin Fulvicin U/F Antibiotic, Antifungal *Non-Steroidal Anti-Inflammatory Drug 86 LOOKING FIT, February 2005 LFFeb05 pgs78-118 12/29/04 4:58 PM Page 88 Generic Name Brand Name Therapeutic Class Sulfadoxine + Pyrimethamine Fansidar Antimalarial, Antiprotozoal Griseofulvin Ultramicrosize Grisactin Ultra Antibiotic, Antifungal Sulfamethizole + Phenazopyridine Thiosulfil-A Urinary analgesic, Antibiotic Guanethidine + Hydrochlorothiazide Esimil Antihypertensive, Thiazide diuretic Sulfamethoxazole Gantanol Antibiotic Haloperidol Haldol Antipsychotic, Tranquilizer Sulfamethoxazole + Phenazopyridine Azo Gantanol Antibiotic, Urinary analgesic Hexachlorophene Phisohex Antibacterial Sulfapyridine (Generic only) Dermatitis herpetiformis suppressant Hydralazine + Hydrochlorothiazide Apresazide Antihypertensive, Thiazide diuretic Sulfasalazine Azulfidine Bowel anti-inflammatory Hydralazine Apresoline-Esidrix Antihypertensive, Thiazide diuretic Sulfinpyrazone Anturane Antigout agent, Antihyperuricemic Hydrochlorothiazide Esidrix Antihypertensive, Thiazide diuretic Sulfasoxazole Gantrisin Antibiotic Hydrochlorothiazide Hydrodiuril Antihypertensive, Thiazide diuretic Sulfasoxazole + Phenazopyridine Azo Gantrisin Antibiotic, Urinary analgesic Hydrochlorothiazide Oretic Antihypertensive, Thiazide diuretic Sulfone Dapsone Antileprosy, Antimalarial Hydrochlorothiazide Oreticyl Antihypertensive, Thiazide diuretic Sunlindac Clinoril (<1%) NSAID,* Antiarthritic Hydrochlorothiazide + Triamterene Dyazide Antihypertensive, Thiazide diuretic Terfenadine Seldane Antihistamine Hydrochlorothiazide Maxzide Antihypertensive, Thiazide diuretic Tetracycline Achromycin Antibiotic Hydroflumethiazide Diucardin Antihypertensive, Thiazide diuretic “ ” Sumycin Antibiotic Hydroflumethiazide Saluron Antihypertensive, Thiazide diuretic Thioridazine Mellaril Antipsychotic, Tranquilizer Hydroflumethiazide + Reserpine Salutensin/ Thiothixene Navane Antipsychotic, Tranquilizer Salutensin-Demi Antihypertensive, Thiazide diuretic Timolol + Hydrochlorothiazide Timolide Beta-adrenergic blocker, Ibuprofen Advil (<1%) NSAID,* Antiarthritic Thiazide diuretic Ibuprofen Motrin (<1%) NSAID,* Antiarthritic Tolazamide Tolinase Antidiabetic (oral), Sulfonylurea Imipramine Tofranil Antidepressant (tricyclic) Tolbutamide Orinase Antidiabetic (oral), Sulfonylurea Indapamide Lozol Antihypertensive, Diuretic Tretinoin Retin-A Antiacne (topical) Interferon ALFA-2B Intron A (<1%) Antiviral agent Triamterene Dyrenium Antihypertensive Diuretic Isocarboxazid Marplan Antidepressant, MAO inhibitor Trifluoperazine Stelazine Antipsychotic, Tranquilizer Isotretinoin Accutane Antiacne Triflupromazine Vesprin Antiemetic, Antipsychotic Ketoprofen Orudis (<1%) NSAID,* Antiarthritic Trimeprazine Temaril Antipsychotic, Tranquilizer Labetalol Normodyne Antihypertensive, Beta- and Trimethoprim Trimpex Antibiotic alpha-adrenergic blocker Trimethoprim + Sulfamethoxazole Bactrim Antibiotic Labetalol + Hydrochlorothiazide Normozide Beta- and alpha-adrenergic “ ” Septra Antibiotic blocker, Thiazide diuretic Trimipramine Surmontil Antidepressant (tricyclic) “ ” Trandate HCT Beta- and alpha-adrenergic blocker, Tripelennamine PBZ Antihistamine Thiazide diuretic Triprolidine Actidil Antihistamine Lisinopril + Hydrochlorothiazide Prinzide Antihypertensive, Thiazide diuretic Triprolidine + Pseudoephedrine Actifed Antihistamine, Decongestant “ ” Zestoretic Antihypertensive, Thiazide diuretic Visblastine Velban Antieoplastic Lovastatin Mevacor Anticholesterol *Non-Steroidal Anti-Inflammatory Drug Maprotiline Ludiomil Antidepressant Meperidine + Promethiazine Mepergan Narcotic analgesic Mesoridazine Serentil Antipsychotic, Tranquilizer Methacycline Rondomycin Antibiotic Methazolamide
Recommended publications
  • Alzheimer's Disease, a Decade of Treatment: What Have We Learned?

    Alzheimer's Disease, a Decade of Treatment: What Have We Learned?

    A Critical Look at Medication Dementia: Alzheimer’s Disease Management Issues in Alzheimer’s Disease R.Ron Finley, B.S. Pharm., R.Ph,CGP Lecturer (Emeritus) and Assistant Clinical Professor, UCSF School of Pharmacy Clinical Pharmacist, UCSF Memory and Aging Center- Alzheimer’s Research Center Educational Objectives Disclosures 1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia. Pfizer Speakers Bureau 2. Name three common side effects of atypical antipsychotic Forest Speakers Bureau drugs. Novartis Speakers Bureau 3. Construct a pharmacological treatment plan for a 77-year-old Rx Consultant Associate Editor patient diagnosed with Alzheimer’s disease and hallucinations. WindChime Consultant 4. Describe the role for antipsychotic, antidepressant, mood HGA HealthCare Consultant stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease. Elder Care Specialist Consultant 5. Cite three potential drug or disease interactions with cholinesterase inhibitors. The Many Faces of Dementia Risk Factors Linked to AD Alzheimer’s Disease Over 65 years of age and increases Vascular: Multi-infarct with age FrontalTemporal Lobe dementia ( FTD) and female Pick’s disease Head injury Lewy Body Dementia Progressive Supranuclear Palsy Factors associated with DM, HTN, CVD Corticobasal Degeneration Genetic: family history, specific Primary Progressive Aphasia chromosome mutations Huntington’s disease
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al

    US 201401.00249A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears et al. (43) Pub. Date: Apr. 10, 2014 (54) THERAPEUTIC TREATMENT A63/37 (2006.01) A613 L/45 (2006.01) (71) Applicants: Douglas Sears, Oak Park, CA (US); A613 L/4458 (2006.01) Michael Reilly, Oak Park, CA (US) (52) U.S. Cl. CPC ............... A61K 45/06 (2013.01); A61 K3I/451 (72) Inventors: Douglas Sears, Oak Park, CA (US); (2013.01): A613 L/4458 (2013.01); A61 K Michael Reilly, Oak Park, CA (US) 3 1/137 (2013.01); A61 K31/165 (2013.01) USPC .......................................................... S14/325 (21) Appl. No.: 14/046,528 (57) ABSTRACT (22) Filed: Oct. 4, 2013 This invention discloses a treatment for a patient receiving O O medication to treat an attention deficit disorder Such as Related U.S. Application Data ADHD wherein the treatment results in a loss of appetite and (60) Provisional application No. 61/744,948, filed on Oct. impairment of the patient's attentiveness. The treatment com 9, 2012, now abandoned. bines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases Publication Classification the caloric intake of a patient, which can increase the patients attentiveness. The combination treatment can be given for an (51) Int. Cl. indefinite, including, without limitation, life-long, to allow a A6 IK 45/06 (2006.01) patient to maintain normal caloric intake during treatment for A6 IK3I/65 (2006.01) an attention deficit disorder. 8aasaias: Patent Application Publication Apr. 10, 2014 Sheet 1 of 22 US 2014/010O249 A1 Figure i: improvement in Atiention with increased Caiotic intake 8aakast Patent Application Publication Apr.
  • Synthetic Drugs

    Synthetic Drugs

    Comprehensive and Confident Identification of Narcotics, Steroids and Pharmaceuticals in Urine David E. Alonso1, Petra Gerhards2, Charles Lyle1 and Joe Binkley1 | 1LECO Corporation, St. Joseph, MI; 2LECO European LSCA Centre, Moenchengladbach, Germany Introduction Experimental Sample A (Traditional Drugs) Sample B (Synthetic Drugs) Monitoring of patients in hospitals and clinics has traditionally relied on Samples Representative Compounds Representative Compounds targeted methods of analysis. These screening methods are not Peak # Name Formula R.T. (s) Area Similarity Mass Delta (mDa) MA (ppm) 1 Creatinine ME C5H9N3O 210 1326229 800 -0.05 -0.43 • Obtained from a collaborating European hospital 3.5e6 3.0e6 Peak # Name Formula R.T. (s) Area Similarity 2 o-Ethynylaniline C8H7N 219 167436 893 0.07 0.63 1 Indole C8H7N 213 2744171 917 comprehensive and result in an incomplete picture of a patient’s 3 2-Methoxy-4-vinylphenol C H O 223 65764 805 0.11 0.73 52 patient monitoring samples 9 10 2 2 Creatinine ME C5H9N3O 216 613318 651 • 2.5e6 4 Nicotine C10H14N2 234 3249121 898 -0.21 -1.29 3 Pyridine, 2-(1-methyl-2-pyrrolidinyl)- C10H14N2 230 24869771 899 activities. Gas chromatography high resolution time-of-flight mass 3.0e6 5 Hordenin C10H15NO 274 949734 775 -0.14 -0.84 4 Parabanic acid, 1-methyl- C4H4N2O3 233 434278 764 Sample preparation 5 Cotinine C10H12N2O 336 27810908 918 • 6 Methylecgonine C10H17NO3 276 104640 835 -0.22 -1.1 spectrometry (GC-HRT) provides a fast and convenient method for 2.0e6 5 6 Caffeine C8H10N4O2 371 3753598 797 2.5e6 7 4-(3-Pyridyl-tetrahydrofuran-2-one C9H9NO2 313 93817 849 -0.11 -0.68 3,4 7 1-methyl-7H-xanthine C6H6N4O2 437 4868196 850 analysis of urine samples.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Hygroscopicity of Pharmaceutical Crystals

    Hygroscopicity of Pharmaceutical Crystals

    HYGROSCOPICITY OF PHARMACEUTICAL CRYSTALS A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY DABING CHEN IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY RAJ SURYANARAYANAN (ADVISER) JANUARY, 2009 © Dabing Chen, January / 2009 ACKNOWLEDGEMENTS I am very grateful to my thesis advisor, Prof. Raj Suryanarayanan, for his constant guidance, support, and encouragement throughout my research. Without his help, the completion of this thesis would be impossible. His friendship and advices are precious to my professional and personal growth and will help me overcome many difficulties in my future career. I would like to take the opportunity to thank Prof. David J.W. Grant, who was my advisor during the first three years in graduate school and led me into the research area of physical pharmacy. It was my great honor to have worked for him, and he will always live as a role model in my life. Many thanks to Dr. Zheng Jane Li at Boehringer Ingelheim Pharmaceuticals (BI) for her invaluable advice as an industrial mentor and also for agreeing to serve on my committee. I sincerely appreciate her helpful discussions, revision of the manuscripts, and supervision of my research. I also want to thank her for providing me the internship opportunity at BI. I thank Dr. Timothy S. Wiedmann and Dr. Theodore P. Labuza for serving on my committee and for critically reviewing my thesis. I also want to thank Dr. Timothy S. Wiedmann for allowing me the use of the HPLC instruments in his lab and also for his advice as the Director of Graduate Studies.
  • I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St

    I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St

    2014;22(1):13-18 TCP Translational and Clinical Pharmacology http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, Korea *Correspondence: S. Han; Tel: +82-2-2258-7326, Fax: +82-2-2258-7876, E-mail: [email protected] Received 31 May 2014 Primary health care providers play a critical role in maintaining public health, and the appropri- Accepted 31 May 2014 ate use of pharmaceutical products is one of the major parts of their practice. This series of articles, pISSN: 2289-0882 entitled ‘Clinical Pharmacology Review for Primary Health Care Providers,’ is intended to help pri- mary health care providers select more appropriate prescriptions for frequently used drugs based on up-to-date information. We expect that this effort will contribute to improvements in public health and diminish unnecessary drug use. Introduction tion on the H1 receptor.[8] THERAPEU Antihistamines include some of the most frequently prescribed drugs in the primary health care environment for the symp- Generations and Classes tomatic relief of allergic diseases, the common cold, urticaria, Many primary health care providers are well-informed about T and insomnia.[1-5] The importance of antihistamines has been the different ‘generations’ of antihistamines but not about the ICS TU emphasized as the prevalence of target diseases increases.[6,7] different ‘classes’ characterized according to chemical structure. However, the appropriate use, clinical effectiveness, and target [1] This discrepancy seems reasonable because ‘inter-generation’ T populations for prescription of antihistamines are still a matter differences are more prominent than ‘inter-class’ differences.
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
  • Cyproheptadine

    Cyproheptadine

    PATIENT & CAREGIVER EDUCATION Cyproheptadine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to ease allergy signs. It is used to treat hives. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? For all patients taking this drug: If you have an allergy to cyproheptadine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Bowel block, enlarged prostate, glaucoma, trouble passing urine, or ulcers in your stomach or bowel. If you are taking certain drugs used for depression like Cyproheptadine 1/9 isocarboxazid, phenelzine, or tranylcypromine, or drugs used for Parkinson’s disease like selegiline or rasagiline. If you are taking any of these drugs: Linezolid or methylene blue. If you are 65 or older. If you are breast-feeding. Do not breast-feed while you take this drug. Children: If your child is a premature baby or is a newborn. Do not give this drug to a premature baby or a newborn. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D

    Treatment of Schizophrenia Course Director: Philip Janicak, M.D

    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between